Q4 2025 Dexcom Inc Earnings Call Transcript
Key Points
- DexCom Inc (DXCM) reported a 13% revenue growth in Q4 2025, exceeding the high end of their guidance.
- The company successfully launched the Dexcom G7 15-day system in the US, receiving positive feedback for its longer wear time and improved accuracy.
- DexCom Inc (DXCM) achieved significant international revenue growth, particularly in markets like Germany, the UK, and France.
- The company improved its gross margin by over 200 basis points in Q4 2025 due to better freight management and reduced scrap rates.
- DexCom Inc (DXCM) closed 2025 with a strong financial position, holding approximately $2 billion in cash and cash equivalents.
- The company faces challenges in expanding coverage for type 2 non-insulin users, with Medicare coverage still pending.
- DexCom Inc (DXCM) anticipates a decline in gross margin in Q4 2026 due to the opening of their Ireland manufacturing facility.
- The company is experiencing competitive pressure, particularly from the launch of Libre 3 in the US.
- There are concerns about the utilization rates for type 2 non-insulin users, which may not match those of insulin users.
- DexCom Inc (DXCM) needs to continue generating evidence to unlock international market access, which can be a lengthy process.
Ladies and gentlemen, good afternoon and welcome to the Dxcom fourth quarter and fiscal year 2025 earnings release conference call.
My name is Abby, and I will be your operator today.
At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. During the question-and-answer session, if you have a question, please press star one on your touchtone phone.
As a reminder, the conference is being recorded.
I will now turn the call over to Mr. Sean Christensen, Vice President of finance and Investor relations. Mr. Christensen, you may begin.
Thank you, operator, and welcome to Dexcom's 4th quarter and fiscal year 2025 earnings call. Our agenda begins with Jake Leach, Dexcom's President and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jeremy Sylvain, our Chief Financial Officer. Following our prepared remarks, we will
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
